IFW may!

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

NARIMATSU et al.

Appln. No. 10/539,450

Filed: December 23, 2005

Confirmation No. 6812

Atty. Ref.: 159-90

T.C. / Art Unit: 1638

Examiner: Not Known

FOR: β1,3-N-ACETYL-D-GALACTOSAMINE TRANSFERASE PROTEIN, NUCLEIC ACID ENCODING THE SAME AND METHOD OF EXAMINING CANCERATION

USING THE SAME

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

May 25, 2006

U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Further to the Information Disclosure Statements (IDS) submitted on June 20, 2005 and April 12, 2006 in this application, attached is Form PTO-1449 listing the enclosed documents. Note that the sequence information of WO 01/79556 is relevant (especially SEQ ID NO:1006), but that the document does not describe expression of a glycotransferase protein or enzymatic activity of a glycotransferase protein.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to enable Applicants to comply fully. In particular, if any of the listed documents are missing or incomplete, please contact the undersigned who will provide another copy.

'NARIMATSU et al. – Appln. No. 10/539,450

As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this information and the listed references are prior art merely because they have been submitted for consideration. Furthermore, no representation is being made that a search has been conducted or that this statement encompasses all possible material information.

Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per M.P.E.P. § 609, are earnestly solicited. The Examiner is invited to contact the undersigned if any further information is needed.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Garv

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

UR

*Examiner

APPLN. NO.

10/539.450

APPLICANT



159-90

NARIMATSU et al.

FILING DATE

GROUP

December 23, 2005

1638

U.S. PATENT DOCUMENTS *EXAMINER FILING DATE INITIAL **DOCUMENT NUMBER** DATE CLASS SUBCLASS IF APPROPRIATE NAME AR BR CR FOREIGN PATENT DOCUMENTS

MAY 2 5 2006

TRANSLATION **DOCUMENT** DATE COUNTRY YES CLASS SUBCLASS NO DR WO 01/79556 10/2001 **WIPO** t Abstrac **ER** 2002-85069 10/2003 Japan FR GR HR IR JR

OTHER DOCUMENTS (including Author, Title, Pertinent pages, Date, etc.) Hiruma et al. "Cloning and analyzing functions of a novel human glycosyltransferase of β3GalNAc-T2 gene" Biotechnol. Symposium Abstracts, 21:137-140 (2003) in Japanese with partial English translation Hiruma et al. "A novel human β1,3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAcβ1-3GlcNAc" J. Biol. Chem. 279:14087-14095 (2004) lwai et al. "Molecular cloning and characterization of a novel UDP-GlcNAc: GalNAc-peptide 61,3-Nacetylglucosaminyltransferase (β 3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans" J. Biol. Chem. 277:12802-12809 (2002) Taga et al. "Sequential changes in glycolipid expression during human B cell differentiation: Enzymatic bases" Biochim. Biophys. Acta 1254:56-65 (1995) Uyama et al. "Molecular cloning and expression of human chondroitin N-acetylgalactosaminyltransferase: The key enzyme for chain initiation and elongation of chondroitin/dermatan sulfate on the protein linkage region tetrasaccharide shared by heparin/heparan sulfate" J. Biol. Chem. 277:8841-8846 (2002) Wandall et al. "Substrate specificities of three members of the human UDP-N-acetyl-α-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2 and -T3" J. Biol. Chem. 272:23503-23514 (1997) PR QR RR SR TR

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

Form PTO-FB-A820 (Also PTO-1449)